Canadian Cancer Trials Group Bulletins

2016

Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

16 Dec 2016

General

Recent Publications
There were two recent publications -- one related to PA.3 and the other related to MAC.5/IBCSG 25-02.

Read more ....

'

CCTG Bulletin in 2017
The first Bulletin of 2017 will be sent on Friday, January 13.

Read more ....

'

CCTG Ops and Stats Office Holiday Closure
The Canadian Cancer Trials Group Central Ops and Stats Office will be closed with limited staff over the holidays.

Read more ....

'

Happy Holidays and Happy New Year!!
The Canadian Cancer Trials Group's Central Operations and Statistics Office wishes everyone a very Merry Christmas, Happy Holidays, and Happy New Year.

Read more ....

'

IND.226 and IND.221 Presented at ENA and WCLC
Results of IND.226 and IND.221 were recently presented at the EORTC-NCI-AACR 2016 Symposium in Munich, Germany and the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Read more ....

'

Two CCTG Trial in CCS's Top 10
Two CCTG trials -- CE.6 and MA.17R -- were included in the Canadian Cancer Society's list of the top 10 research impact stories for 2016.

Read more ....

'

Trial Management Group

Trial Closed to Accrual / Trial Permanently Closed
SRC.7 (Alliance A091105) was recently closed to accrual and REC.1 (CALGB 90206) was recently permanently closed.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

02 Dec 2016

General

2016 EORTC-NCI-AACR Symposium
Two CCTG IND trials - IND.221 and IND.226 - were presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany. Additionally, Dr. Lesley Seymour, IND Director, presented the newly-developed iRECIST guidelines.

Read more ....

'

Recent Publication
There was one recent publication related to CCTG MA.27, A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

Read more ....

'

58th American Society of Hematology Annual Meeting
CCTG will be presenting one oral presentation and one poster and is part of four other abstracts at the American Society of Hematology (ASH) Annual Meeting and Symposium being held in San Diego from December 3-6, 2016.

Read more ....

'

2016 San Antonio Breast Cancer Symposium
CCTG is presenting three posters at the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Centre from December 6-10, 2016.

Read more ....

'

Trial Management Group

Trial Activation
One trial, IND.224 - A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases - was recently centrally activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

18 Nov 2016

General

Recent Publication
There was one recent publication reporting primary results of IND.193 and IND.194 -- The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Read more ....

'

Group Administrators Office

2017 CCTG Recognition Awards
The Central Operations and Statistics Office is seeking nominations for the 2017 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group.

Read more ....

'

Trial Management Group

Permanent Trial Closure
HD.7 (E2496) - A Randomized Phase III Trial of ABVD Versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease - is now permanently closed.

Read more ....

'

Trial Activations
Two trials -- MAC.20 (A011401) and PR.19 -- were recently centrally activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

21 Oct 2016

General

Mark Your Calendar - TAT 2017
The 15th International Congress on Targeted Anticancer Therapies (TAT) is scheduled for March 6-8, 2017 in Paris, France.

Read more ....

'

Recent Publications
There were two recent publications -- one reporting the primary results of CE.5 (EORTC 22033-26033) and the other reporting health-related quality of life in CE.5.

Read more ....

'

Trial Management Group

Trial Closed to Accrual
NEC.3 (Alliance 021202), A Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumours, was closed to accrual on October 7, 2016.

Read more ....

'

Trial Activation
IND.228, A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours, was centrally activated on October 19, 2016.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

07 Oct 2016

General

SAVE THE DATE - New Investigator Clinical Trials Course
Please mark your calendars for the 2017 New Investigator Clinical Trials Course, which is scheduled for August 9-11, 2017 at the Donald Gordon Centre in Kingston, Ontario.

Read more ....

'

Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Monday, October 10, 2016 for Thanksgiving. Regular business hours will resume on Tuesday, October 11 at 8:30 am EDT.

Read more ....

'

Breast International Group (BIG) Research in Focus
The Breast International Group (BIG) Research in Focus is now available online.

Read more ....

'

Trial Management Group

Trial Activation
One trial, IND.227 - A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma - was centrally activated today, October 7, 2017.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

23 Sep 2016

General

Recent Publication
There was one recent publication reporting the primary results of IND.207 - A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma.

Read more ....

'

CCTG Trialblazers Get Muddy for CCS
On Saturday, September 17, the CCTG Trialblazers participated in the Canadian Cancer Society's Mudmoiselle Ladies' Mud Run held in Kingston. They raised over $2500 and had a blast doing it!

Read more ....

'

The Tragically Hip Tour Raises Over $1M
The Tragically Hip's summer tour has raised over $1 million to support brain cancer research. Of that, $800,000 in donations were made to The Sunnybrook Foundation's Gord Downie Fund for Brain Cancer Research. The CCS is directing $400,000 to the CCTG.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

09 Sep 2016

General

Recent Publications
There were two recent publications -- one related to BR.10, which describes results of an exploratory economic analysis to assess the potential cost-effectiveness of using the 15-gene signature in guiding adjuvant chemotherapy decisions.

Read more ....

'

Trial Management Group

Trials Closed to Accrual
Three trials were recently closed to accrual -- PA.6 (ACCORD 24), PRC.4 (Alliance A031201), and LYC.1 (E1411).

Read more ....

'

Trial Activations
Two trials were recently centrally activated -- PA.7 and IND.232.

Read more ....

'

CRA Volunteer Needed for CRA Executive!!
The Canadian Cancer Trials Group is actively seeking Clinical Research Associate (CRA) representatives from Canadian Member sites to participate in the CRA Executive Committee.

Read more ....

'

CRA Volunteers Needed for Disease Site Executives!
The Canadian Cancer Trials Group is actively seeking Clinical Research Associate (CRA) representatives from Canadian Member sites to sit on several Disease Site Committee Executives.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

12 Aug 2016

General

Recent Publications
There were 4 recent publications -- one related to MY.10, one related to EN.7 (DCGOG PORTEC-3), one related to SC.23, and another related to MAC.4 (IBCSG 24-02)/MAC.5.

Read more ....

'

Trial Management Group

Trial Activations
Two trials were recently centrally activated ... CO.26 and REC.3 (SWOG S1500).

Read more ....

'

Permanent Trial Closure
CE.6 - A Randomized Phase III Study of Temozolomide and Short-Course Radiation vs. Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients - was recently permanently closed.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

15 Jul 2016

General

Recent Publications
There have been a number of recent publications, including final results of MA.17R published in the New England Journal of Medicine and presented at the 2016 ASCO Plenary Session.

Read more ....

'

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.

Read more ....

'

CCTG Members Named to the Order of Canada
Congratulations to CCTG members, Drs. Gerald Batist and Mark Levine, who were recently named Members of the Order of Canada.

Read more ....

'

Trial Management Group

Permanent Trial Closures
CCTG OV.21, AL.3 (CALGB 9710) and CLC.1 (CALGB C10501) have all been permanently closed.

Read more ....

'

Trial Activation
ME.13 - A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) - was centrally activated on July 4, 2016.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

03 Jun 2016

General

Recent Publications
There were a number of recent publications, including one reporting primary results for OV.18 (MRC ICON6) published in The Lancet.

Read more ....

'

ASCO 2016
A number of abstracts related to CCTG trials or trials which included CCTG participation will be presented at the 2016 Annual American Society of Clinical Oncology Annual Meeting, including final results of MA.17R and CE.6.

Read more ....

'

7 Days in May Visit Central Office
On Monday, May 26, the CCTG Central Office had some very special visitors - the 7 Days in May riders on their fourth annual trek around Lake Ontario in their quest to raise funds to cure pancreatic cancer.

Read more ....

'

Trial Management Group

Trials Closed to Accrual
CLC.2 (A041202) and CLC.2E were closed to accrual on May 1, 2016.

Read more ....

'

Health Canada Approves Two New IND Trials
IND.227 and IND.232 were recently approved by Health Canada. It is anticipated that these trials will be centrally activated in late June / early July. We are looking for Canadian centres who may wish to participate in these trials.

Read more ....

'

Permanent Trial Closures
SR.6 (TH-CR-406 / SARC021) and PR.8 (S9346) have been permanently closed.

Read more ....

'

Job Opportunities at CCTG Central Office
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a Study Coordinator and a Communications Leader.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

20 May 2016

General

Recent Publications
There were four recent publications, including one reporting final results of HD.8 (EORTC 20012) - BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's lymphoma.

Read more ....

'

37th Annual Meeting of the Society for Clinical Trials
The CCTG Central Operations and Statistics Centre is delighted to have been represented by a number of staff with oral presentations and posters covering a wide range of topics in clinical trials.

Read more ....

'

Today Is International Clinical Trials Day!
International Clinical Trials Day, launched in 2005, is held on or around May 20 each year to commemorate the day that James Lind started his famous clinical trial on scurvy in 1747 and laid the foundation for modern clinical research.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Central Office Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Monday, May 23, 2016 for Victoria Day. Regular business hours will resume on Tuesday, May 24 at 8:30 am EDT.

Read more ....

'

Trial Management Group

Trial Closed to Accrual
MEC.4 (Alliance A091201) - Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma - was recently closed to accrual.

Read more ....

'

Trial Activations
Two Investigational New Drug trials were recently centrally activated -- IND.225 and IND.231.

Read more ....

'

CCTG Pharmacists Network is in Need of Volunteers!!
The Pharmacists Network is an essential committee of Central Office. Do you have ideas/suggestions that you would like to see implemented at Central Office? Committee participation will give you a voice for the changes/suggestions you seek!!

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

06 May 2016

General

Recent Publications
There were two recent publications both reporting primary results -- IND.187 and IND.197.

Read more ....

'

IND Executive -- New Investigator Engagement Pilot Project
In an effort to foster newer investigator interest and participation in early clinical trials, the Investigational New Drug (IND) Program will be piloting a one-year membership on the IND Executive Committee.

Read more ....

'

Group Administrators Office

Spring Meeting 2016 - Accreditation and Expenses
Please click "read more" below for information about obtaining your CME Certificate and, if you were a funded participant, about claiming your expenses.

Read more ....

'

Trial Management Group

Division 5 Training Mandatory for all CCTG trials with a CTA
On June 1, 2016 Canadian Cancer Trials Group's Division 5 training program will become mandatory for trials requiring a CTA application with Health Canada.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 Apr 2016

General

Recent Publication
A recent publication used MA.17 data to retrospectively explore the relationship between diabetes and other related co-morbidities on prognosis and the predictive effect of extended letrozole treatment after tamoxifen.

Read more ....

'

Group Administrators Office

Spring Meeting Information
The Canadian Cancer Trials Group 2016 Annual Spring Meeting of Participants is being held next week, April 29 - May 1, at the Chelsea Hotel in Toronto.

Read more ....

'

Canadian Cancer Trials Group Recognition Awards
We are pleased to let you know the recipients of this year's Canadian Cancer Trials Group Recognition Awards. These awards will be presented at the Plenary and Recognition Awards ceremony at Spring Meeting on Friday, April 29 @ 4:30 pm.

Read more ....

'

Spring Meeting Saturday Highlights
We are very pleased to let you know the General Meeting and the Cosbie Lecture are planned for Saturday, April 30 from 4:30-6:00 pm during Spring Meeting. This year's Cosbie Lecturer is Dr. Mary Gospodarowicz.

Read more ....

'

Spring Meeting Friday Highlights
As Spring Meeting approaches, we wanted to highlight some of the special activities that will be taking place on Friday, April 29 from 4:30-7:00 pm, including A Plenary Session, Recognition Awards Ceremony, and "Serious Converse Event" Reception.

Read more ....

'

Office of Compliance and Oversight

2016 Joan K. Mauer Memorial Quality Assurance Award
We are very pleased to announce that Ms. Ing Collins from the Jurvanski Cancer Centre at Hamilton Health Sciences Centre is the 2016 recipient of the Joan K. Mauer Memorial Quality Assurance Award.

Read more ....

'

Office of the Director

CCS Relay for Life -- CCTG Trialblazers
Relay for Life is CCS's largest funding raising event. Once again, the Central Office has formed a team, The Trialblazers, to participate in the Relay for Life in Kingston on June 4, 2016. Support of the Trialblazers, and the CCS, would be appreciated!!

Read more ....

'

Trial Management Group

Trial Activations
Two trials were recently centrally activated -- IND.229 and BRC.6 (SWOG S1400) - A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map).

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

08 Apr 2016

Group Administrators Office

Canadian Cancer Trials Group Recognition Awards
We are pleased to let you know the recipients of this year's Canadian Cancer Trials Group Recognition Awards. These awards will be presented at the Plenary and Recognition Awards ceremony at Spring Meeting on Friday, April 29 @ 4:30 pm.

Read more ....

'

Spring Meeting Friday Highlights
As Spring Meeting approaches, we wanted to highlight some of the special activities that will be taking place on Friday, April 29 from 4:30-6:00 pm, including A Plenary Session, Recognition Awards Ceremony, and "Serious Converse Event" Reception.

Read more ....

'

Spring Meeting Saturday Highlights
We are very pleased to let you know the General Meeting and the Cosbie Lecture are planned for Saturday, April 30 from 4:30-6:00 pm during Spring Meeting. This year's Cosbie Lecturer is Dr. Mary Gospodarowicz.

Read more ....

'

Spring Meeting Registration
Spring Meeting online registration will close Thursday, April 21, 2016. Please be sure to register prior to this date to ensure a faster on-site registration process as a name tag and meeting materials will be ready for pick-up.

Read more ....

'

Office of Compliance and Oversight

2016 Joan K. Mauer Memorial Quality Assurance Award
We are very pleased to announce that Ms. Ing Collins from the Jurvanski Cancer Centre at Hamilton Health Sciences Centre is the 2016 recipient of the Joan K. Mauer Memorial Quality Assurance Award.

Read more ....

'

Trial Management Group

Trial Activation
MYX.1 (MCRN-003) - A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies - was recently activated.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

24 Mar 2016

Group Administrators Office

Holiday Closure
The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Friday, March 25, 2016 in observance of Good Friday. Regular business hours will resume on Monday, March 28 at 8:30 am EDT.

Read more ....

'

2016 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2016 Annual Spring Meeting of Participants will be held April 29 - May 1, 2016 at The Chelsea Hotel in Toronto.

Read more ....

'

Trial Management Group

Trial Activations
Two trials were recently activated -- CEC.6 (Alliance N0577) and MAC.18 (IBCSG18-14/Alliance 221405).

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

14 Mar 2016

General

Recent Publications
There were two recent publications, including one which aimed to estimate the total drug cost avoidance and pathology cost avoidance for Canadian patients enrolled in relevant CCTG phase III trials.

Read more ....

'

Group Administrators Office

2016 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2016 Annual Spring Meeting of Participants will be held April 29 - May 1, 2016 at The Chelsea Hotel in Toronto.

Read more ....

'

Trial Management Group

Let's Boost Accrual! How can CCTG help?
We are looking for your input, suggestions, and feedback regarding how the CCTG Central Office can help centres improve accrual - specifically after local activation.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

26 Feb 2016

General

Dr. Mary Gospodarowicz Awarded O. Harold Warwick Prize
Dr. Mary Gospodarowicz is the recipient of the Canadian Cancer Society's O. Harold Warwick Prize for outstanding achievements in cancer control research.

Read more ....

'

Recent Publication
There was one recent publication reporting results of a combined analysis of AL.4 and AL.5 to determine whether pediatric-inspired chemotherapy regimens do offer improved patient outcomes compared to hematopoietic cell transplantation.

Read more ....

'

Group Administrators Office

2016 Annual Spring Meeting
The Canadian Cancer Trials Group 2016 Annual Spring Meeting of Participants will be held April 30 - May 1, 2016 at the Chelsea Hotel in Toronto.

Read more ....

'

Trial Management Group

Pharmacists Network Steering Group Needs You!
The Pharmacists Network Steering Committee is actively seeking representatives for both the Steering Group (Eastern Rep - Atlantic Provinces) and a Pharmacist Representative for both the Breast and Gastrointestinal Disease Site Committees.

Read more ....

'

Let's Boost Accrual! How can CCTG help?
We are looking for your input, suggestions, and feedback regarding how the CCTG Central Office can help centres improve accrual - specifically after local activation.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

12 Feb 2016

General

Recent Publication
There was one recent publication related to SC.20 reporting results on a study to establish a survival prediction model in the setting of a randomized trial of re-irradiation for painful bone metastases.

Read more ....

'

2016 Annual Spring Meeting of Participants
The 2016 Annual Spring Meeting of Participants will be held April 29-May 1 at the Chelsea Hotel in Toronto. Full-funded invitations were sent electronically on January 29, 2016.

Read more ....

'

Canadian Cancer Trials Group Highlighted
The Canadian Cancer Trials Group, including investigators Jim Biagi, Michael Brundage, and Annette Hay, are highlighted in Queen's research magazine, (e)Affect.

Read more ....

'

Group Administrators Office

Central Operations and Statistics Office - Family Day
The Canadian Cancer Trials Group Central Operations and Statistics Office will be closed on Monday, February 15, 2016 to celebrate Family Day. Regular business hours will resume on Tuesday, February 16 at 8:30 am EST.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

29 Jan 2016

General

7 Days in May Contributes $67,674
We are extremely grateful to the 7 Days in May Foundation who, for the third year in a row, is donating the proceeds of its seven-day ride around Lake Ontario to the Canadian Cancer Trials Group in support of pancreatic cancer research.

Read more ....

'

Dr. Frances Shepherd Named to the Order of Canada
Dr. Shepherd, past Chair of the Canadian Cancer Trials Group Lung Committee, has been named an Officer of the Order of Canada for her leadership in improving treatment options and outcomes for individuals with advanced lung cancer.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Recognition Awards
THE DEADLINE FOR NOMINATIONS FOR THE GROUP RECOGNITION AWARDS IS FEBRUARY 5!! If you know someone deserving of one of these awards, please nominate them now!!

Read more ....

'

2016 Annual Spring Meeting
The Canadian Cancer Trials Group 2016 Annual Spring Meeting of Participants will be held April 29-May 1, 2016 at the Chelsea Hotel, Toronto. We are aiming to send Full-Funded invitations by end of the day today.

Read more ....

'

Office of the Director

NCIC CTG is now the Canadian Cancer Trials Group
As of January 18, the NCIC CTG has a new name - the Canadian Cancer Trials Group. Please note that email addresses and website url remain the same.

Read more ....

'

Trial Management Group

Trial Activation
MEC.5 (SWOG S1404) - A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma - was centrally activated on January 15, 2016.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Special Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Special Bulletin

18 Jan 2016

Office of the Director

Canadian Cancer Trials Group
As of today, January 18, the NCIC CTG has a new name - the Canadian Cancer Trials Group. Please note that email addresses and website url remain the same.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

15 Jan 2016

General

Recent Publications
There were 3 recent publications, including one reporting the primary results of AL.4 (DFCI 01-175) - A Multi-Center Phase II Study in Adults with Untreated Acute Lymphoblastic Leukemia.

Read more ....

'

SC.23 Results Among CCS 2015 Top 10 Research Impact Stories
The results of SC.23, which showed that dexamethasone lowers the rate of pain flare in cancer patients with bone metastases undergoing radiation therapy for symptom control, was included among CCS's Top 10 Research Impact Stories of 2015.

Read more ....

'

HOT OFF THE PRESS!
Whether you're a clinical trials nurse, advanced practice nurse, student of nursing and research, or research scientist, you'll want a copy of the new Manual for Clinical Trials Nursing, Third Edition.

Read more ....

'

Group Administrators Office

Canadian Cancer Trials Group Recognition Awards
The Central Operations and Statistics Office is seeking nominations for the 2016 Recognition Awards honouring individuals and teams who have contributed significantly to the mission and activities of the Group.

Read more ....

'

2016 Annual Spring Meeting of Participants
The 2016 Annual Spring Meeting of Participants will be held April 29 - May 1, 2016 at the Chelsea Hotel in Toronto. Invitations will be sent in the coming weeks.

Read more ....

'

Trial Management Group

Trial Activation
One trial was recently activated -- IND.222 - A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme.

Read more ....

'

Trial Closed to Accrual
Canadian Cancer Trials Group CEC.3 (NCCTG N107C) - A Phase III Study of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease - will soon reach its accrual goal and has been closed to accrual.

Read more ....

'

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletins